The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | The IASLC: implementing personalized medicine in lung cancer
Giorgio Vittorio Scagliotti, MD, PhD, of the University of Turin, Turin, Italy, discusses how the International Association for the Study of Lung Cancer (IASLC) has helped implement the concept of personalized medicine into routine clinical practice. Speaking at the European Lung Cancer Congress (ELCC), held in Geneva, Switzerland, Prof. Scagliotti explains how the IASLC has increased both physician and public awareness of the latest treatment opportunities, by means such as atlases of diagnosis.
